ABCB1: ATP-dependent translocase ABCB1
Translocates phospholipids and drugs across the membrane.
- Drugs that act on it: 5
- Approved: 0
- In phases 1 to 3: 5
- Sponsors: 4
Who is on it, and how far along
Every drug ChEMBL records acting on ABCB1, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 4
- Protein or peptide 1
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- Health Hope Pharma120%
- Kanisa Pharmaceuticals120%
- QLT120%
- Vertex Pharmaceuticals120%
| Encequidar | Phase 3 | Health Hope Pharma | Small molecule | Inhibitor | 3 |
| Tariquidar | Phase 3 | QLT | Small molecule | Inhibitor | 0 |
| Valspodar | Phase 3 | — | Protein or peptide | Inhibitor | 0 |
| Zosuquidar | Phase 3 | Kanisa Pharmaceuticals | Small molecule | Inhibitor | 0 |
| Biricodar | Phase 2 | Vertex Pharmaceuticals | Small molecule | Inhibitor | 0 |
| A Study to Investigate the Effect of Food on the Bioavailability of Oral Paclitaxel Administered With Encequidar in Participants With Advanced Solid Tumors | Encequidar | Phase 1 | Not yet recruiting | Health Hope Pharma | May 12, 2026 |
| Oral Paclitaxel + Encequidar vs IV Paclitaxel in Treatment of HER2 Negative Metastatic Breast Cancer | Encequidar | Phase 3 | Not yet recruiting | Health Hope Pharma | Feb 19, 2025 |
| I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | Encequidar | Phase 2 | Recruiting | QuantumLeap Healthcare Collaborative | Jan 5, 2010 |
- Response to tramadol0.55
- Encephalopathy, acute transient0.42
- Acute myeloid leukemia0.39
- Inflammatory bowel disease0.39
- Portal hypertension0.36
- Epilepsy0.35
- Gastric cancer0.35
- Non-small cell lung carcinoma0.34
- Breast cancer0.32
- Plasma cell myeloma0.28
- Myelodysplastic syndrome0.27
- Idiopathic generalized epilepsy0.26
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4302, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. Gene name, function (UniProt P08183, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets